Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals.
Anderson
T D
TD
Department of Toxicology and Pathology, Hoffmann-La Roche Inc., Nutley, New Jersey 07110.
Hayes
T J
TJ
Powers
G D
GD
Gately
M K
MK
Tudor
R
R
Rushton
A
A
D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000473:pathology; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005260:Female; D005677:G(M1) Ganglioside / Q000276:immunology; D006529:Hepatomegaly / Q000139:chemically induced / Q000473:pathology; D007116:Immunization, Passive; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology; D007376:Interleukin-2 / Q000008:administration & dosage / Q000633:toxicity*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000473:pathology; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D011654:Pulmonary Edema / Q000139:chemically induced / Q000473:pathology; D011657:Pulmonary Eosinophilia / Q000139:chemically induced / Q000473:pathology; D051381:Rats; D017472:Receptors, Interleukin-1 / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000633:toxicity; D016511:Severe Combined Immunodeficiency / Q000628:therapy; D013163:Splenomegaly / Q000139:chemically induced / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014781:Viscera / Q000473:pathology
D007376:Interleukin-2; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside